Prasugrel for the treatment of acute coronary syndromes with percutaneous coronary intervention
| Status: |
History |
| Expected date of issue: |
October 2009 |
| Referral date: |
June 2009 |
| Wave: |
17 |
| Process: |
STA |
| Topic area:
|
NICE project team
| Executive Lead: |
Gillian Leng
|
| Technical Lead: |
Ruaraidh Hill
|
| Communications manager: |
Phil Ranson
|
| Project manager: |
Laura Malone
|
Provisional schedule
| Closing date for invited submissions / evidence submission: |
09 February 2009 |
| 1st appraisal committee meeting: |
14 May 2009 |
| 2nd appraisal committee meeting |
15 July 2009 |
Consultees and commentators
|
| Consultees |
Commentators (no right to submit or appeal) |
|
Manufacturers / Sponsors
- Eli Lilly & Co (prasugrel)
Patient / carer Groups
- Action Heart
- Heart Care Partnership (UK)
Professional groups
- British Cardiovascular Society
- British Geriatrics Society
- British Heart Foundation
- British Institute of Radiology
- Royal College of Nursing
- Royal Collegeof Physicians
- British Atherosclerosis Society
Others
- Department of Health
- Welsh Assembly Government
|
General
- Department of Health, Social Services and Public Safety for Northern Ireland
Comparator manufacturer(s)
- Sanofi-Aventis (clopidogrel)
- Bristol-Myers Squibb Pharmaceuticals (clopidogrel)
- Daiichi-Sankyo
Relevant research groups
Evidence Review Group
- Liverpool Reviews & Implementation Group, University of Liverpool
- National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme)
Associated Guideline Groups
- National Collaborating Centre for Chronic Conditions
Associated Public Health Groups
|
|
Key documents
This page was last updated: 30 March 2010
